Here’s my response….. I’m so glad you bro

Here’s my response…..

I’m so glad you brought up J&J.
Since YOU brought J&J up and it has been brought in the past from posters on this board, I would love to respond and add to your post.
In the early 90’s I invested into a Biotech company…. Amylin Pharmaceuticals
They had two drugs in the pipeline and both entering into a phase ll study.

Byetta… a once a week oral for Type ll diabetes.
Symlin… an injectable for Type l diabetes.

It was around that time J&J collaborated with Amylin’s Byetta drug and taking the lead in filling the Phase ll study.
I recall that there was some confrontation between Amylin’s scientists and J&J scientists pertaining to the Titration study.
It was J&J conducting the study and rushing it to market.
FDA did not approve but stated needed more info.
J&J decided to withdraw their collaboration and gave all rights back to Amylin.
Amylin was able to secure funding as their lead scientist proceeded to complete the Phase ll study and it was finally approved by the FDA.
As Byetta was entering into phase lll study, out of the blue and a surprise to all us investors, Eli Lilly entered into a collaboration agreement for Byetta
Byetta & Symlin both were approved back to back a few months apart in 2005.
It was a long journey with a few set backs for Amylin.
Founded in 1987, as you can see, Biotech takes a lot of patience, time and money for FDA approvals.
So we now can put J&J to rest as being a huge loser here !!!